Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SOMOPHYLLIN-CRT vs AEROLATE SR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Theophylline acts as a bronchodilator via nonselective phosphodiesterase inhibition, increasing intracellular c AMP levels. It also antagonizes adenosine receptors and may have anti-inflammatory effects.
AEROLATE SR is a sustained-release formulation of theophylline, a methylxanthine bronchodilator. It acts by inhibiting phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cyclic AMP (c AMP) levels. This results in relaxation of bronchial smooth muscle and suppression of the response of airways to stimuli. Theophylline also has anti-inflammatory effects, including inhibition of late-phase allergen-induced responses and reduction of eosinophil infiltration.
Treatment of asthma and chronic obstructive pulmonary disease (COPD),Apnea of prematurity (off-label),Facilitation of weaning from mechanical ventilation in neonates (off-label)
Treatment of symptoms and reversible airway obstruction associated with chronic asthma,Chronic obstructive pulmonary disease (COPD),Apnea of prematurity (off-label)
Theophylline 400 mg orally once daily (24-hour extended-release). Titrate based on serum theophylline levels; target trough 5-15 mcg/m L.
400-800 mcg inhaled twice daily. For acute bronchospasm, 200-400 mcg as needed.
Terminal elimination half-life: 8-10 hours in adults (non-smokers); prolonged to 12-16 hours in elderly or hepatic impairment; reduced to 4-6 hours in smokers (CYP1A2 induction).
Terminal elimination half-life 12 hours (range 10–15 h) in adults; prolonged in hepatic impairment (up to 24 h) and elderly.
Primarily hepatic via cytochrome P450 enzymes, mainly CYP1A2, with minor contributions from CYP2E1 and CYP3A4. Metabolism is saturable, leading to nonlinear pharmacokinetics. Less than 15% excreted unchanged in urine.
Primarily hepatic via cytochrome P450 enzymes (CYP1A2, CYP2E1, and CYP3A4). Theophylline is metabolized to 1,3-dimethyluric acid, 1-methyluric acid, and 3-methylxanthine.
Primarily hepatic metabolism (90%) via CYP1A2 and CYP3A4; renal excretion of unchanged drug accounts for ~10% in adults, with minor biliary/fecal elimination (<1%).
Renal: 60% as unchanged drug; biliary/fecal: 30% as metabolites; 10% as unchanged in feces.
~40% bound to albumin (primarily); binding is concentration-independent.
55–65% bound to plasma proteins, primarily albumin.
0.4-0.6 L/kg (slightly higher in infants); approximates total body water; distributes widely into tissues including breast milk and CNS.
0.4–0.6 L/kg, indicating distribution into total body water.
Oral immediate-release: 80-100%; Oral sustained-release: 90-100% (with less fluctuation); Rectal: 75-90% (variable due to absorption).
Oral: 90–100% for sustained-release formulation; food decreases rate but not extent (AUC unchanged).
No specific dose adjustment required for GFR >30 m L/min. For GFR 10-30 m L/min: reduce dose by 25% and monitor levels. For GFR <10 m L/min: reduce dose by 50% and monitor closely.
No dose adjustment required for renal impairment.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 50% and monitor levels. Child-Pugh Class C: reduce dose by 75% or consider alternative; monitor levels closely.
Use with caution in severe hepatic impairment (Child-Pugh class C); consider dose reduction by 50%.
Children >1 year: initial dose 10-16 mg/kg/day orally q12h (extended-release). Titrate to serum theophylline levels of 5-15 mcg/m L. Maximum 400 mg/day or 16 mg/kg/day, whichever is less.
Children 6-12 years: 200-400 mcg inhaled twice daily. Children over 12 years: same as adult dose.
Elderly patients: start at lowest possible dose (e.g., 200-300 mg once daily) due to reduced clearance. Monitor serum theophylline levels closely; target lower end of therapeutic range (5-12 mcg/m L). Avoid use if possible due to increased risk of toxicity.
Start at lower end of dosing range (400 mcg twice daily) and titrate to response; monitor for systemic effects.
Theophylline has a narrow therapeutic index; toxicity can occur at doses only slightly above therapeutic levels. Serious and potentially fatal adverse events, including seizures and cardiac arrhythmias, can occur, especially in patients with preexisting conditions or those receiving concurrent medications that affect theophylline clearance.
No FDA black box warning exists for this drug.
Monitor serum theophylline concentrations closely due to narrow therapeutic index (10-20 mcg/m L).,Use with caution in patients with cardiac disorders (e.g., arrhythmias), hepatic impairment, renal dysfunction, seizure disorders, and in elderly patients.,May exacerbate gastric ulcers and gastroesophageal reflux.,Drug interactions: CYP1A2 inhibitors (e.g., cimetidine, fluoroquinolones, macrolides) increase levels; CYP1A2 inducers (e.g., smoking, rifampin, phenytoin) decrease levels.
Theophylline has a narrow therapeutic index; serum levels must be monitored to avoid toxicity. Toxicity can include seizures, cardiac arrhythmias, and death. Caution in patients with heart failure, hepatic impairment, or those over 55 years. Risk of toxicity increased by concurrent medications such as cimetidine, fluoroquinolones, and macrolides.
Hypersensitivity to theophylline or any component of the formulation,Pre-existing seizure disorders (relative),Active peptic ulcer disease (relative),Uncontrolled cardiac arrhythmias (relative)
Hypersensitivity to theophylline or any component of the formulation; active seizure disorder; untreated cardiac arrhythmias; severe hypertension; hyperthyroidism; peptic ulcer disease; caution with concurrent use of ephedrine or other sympathomimetics.
Avoid charcoal-broiled foods as they may decrease theophylline levels. High-fat meals can alter absorption; take consistently with regard to meals. Caffeine-containing foods and beverages should be limited due to additive stimulation.
High-fat meals may delay absorption. Avoid charcoal-grilled foods and large amounts of caffeine. Grapefruit juice may increase theophylline levels; limit intake.
Theophylline (active ingredient in SOMOPHYLLIN-CRT) is classified as FDA Pregnancy Category C. First trimester: Limited human data; animal studies show embryotoxicity at high doses but no major malformations. Second and third trimesters: No established teratogenicity; may cause neonatal toxicity (irritability, jitteriness, vomiting) if maternal levels are high near term. Use only if benefit outweighs risk.
Pregnancy Category C. In first trimester: insufficient human data; animal studies show adverse effects at high doses. Second and third trimesters: may cause fetal tachycardia, hypoglycemia, and reduced uterine contractility; avoid use near term due to potential for neonatal bradycardia and hypoglycemia.
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.67. Breastfeeding is generally considered compatible but may cause irritability or sleep disturbances in the infant. Monitor infant for signs of theophylline toxicity. Use lowest effective maternal dose.
Salbutamol is excreted into breast milk in minimal amounts; estimated infant dose <2% of maternal weight-adjusted dose. No known adverse effects in nursing infants. M/P ratio not established. Use with caution.
During pregnancy, theophylline clearance may increase (especially in second and third trimesters), requiring dose adjustments. Monitor serum concentrations closely and increase dose as needed to maintain therapeutic levels. Clearance returns to non-pregnant levels postpartum.
No dose adjustment required for inhaled salbutamol. Increased clearance in late pregnancy may necessitate higher doses for systemic effects; monitor clinical response and adjust accordingly.
SOMOPHYLLIN-CRT (theophylline) is a controlled-release formulation for chronic asthma/COPD. Monitor serum theophylline levels (target 5-15 mcg/m L). Avoid in active seizures. Use with caution in hepatic impairment, heart failure, and elderly. Cimetidine, fluoroquinolones, and macrolides increase levels; smoking and phenytoin decrease levels.
AEROLATE SR contains theophylline; narrow therapeutic index (10-20 mcg/m L). Monitor serum levels, especially with CYP1A2 inhibitors (e.g., ciprofloxacin, fluvoxamine) or inducers (e.g., carbamazepine, phenytoin). SR formulation avoids peak-trough fluctuations; do not crush or chew. Caution in heart failure, hepatic impairment, and elderly.
Swallow tablets whole; do not crush or chew.,Take at the same time each day with a full glass of water.,Avoid excessive caffeine (coffee, tea, cola, chocolate) to prevent increased stimulation.,Report nausea, vomiting, insomnia, palpitations, or seizures immediately.,Do not change brand or formulation without consulting your doctor.,Store at room temperature, away from moisture.
Take exactly as prescribed; do not crush or chew the sustained-release tablet.,Do not stop suddenly; sudden withdrawal may worsen breathing.,Avoid excessive caffeine (coffee, tea, chocolate) as it may increase side effects.,Report nausea, vomiting, insomnia, palpitations, or seizures immediately.,Keep regular appointments for blood level monitoring.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SOMOPHYLLIN-CRT vs AEROLATE SR, answered by our medical review team.
SOMOPHYLLIN-CRT is a Bronchodilator that works by Theophylline acts as a bronchodilator via nonselective phosphodiesterase inhibition, increasing intracellular c AMP levels. It also antagonizes adenosine receptors and may have anti-inflammatory effects.. AEROLATE SR is a Bronchodilator that works by AEROLATE SR is a sustained-release formulation of theophylline, a methylxanthine bronchodilator. It acts by inhibiting phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cyclic AMP (c AMP) levels. This results in relaxation of bronchial smooth muscle and suppression of the response of airways to stimuli. Theophylline also has anti-inflammatory effects, including inhibition of late-phase allergen-induced responses and reduction of eosinophil infiltration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SOMOPHYLLIN-CRT and AEROLATE SR depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SOMOPHYLLIN-CRT is: Theophylline 400 mg orally once daily (24-hour extended-release). Titrate based on serum theophylline levels; target trough 5-15 mcg/m L.. The standard adult dose of AEROLATE SR is: 400-800 mcg inhaled twice daily. For acute bronchospasm, 200-400 mcg as needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SOMOPHYLLIN-CRT and AEROLATE SR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SOMOPHYLLIN-CRT is classified as Category C. Theophylline (active ingredient in SOMOPHYLLIN-CRT) is classified as FDA Pregnancy Category C. First trimester: Limited human data; animal studies show embryotoxicity at high doses. AEROLATE SR is classified as Category C. Pregnancy Category C. In first trimester: insufficient human data; animal studies show adverse effects at high doses. Second and third trimesters: may cause fetal tachycardia, hypo. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.